Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

Presentation Controversies and Advances 2025

Antianginals or Stents are Reasonable Alternatives for Patients with Symptomatic CAD

Presenter: Rasha Al-Lamee

January 31, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

Presentation TCT 2024

Coronary Microvascular Disease -- How Do We Move the Field Forward?

Presenter: Rasha Al-Lamee

October 30, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

Shelley Wood

September 03, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Presentation TCT 2023

My Step-by-step Approach to Avoid Common Mistakes in Measuring Invasive Physiology

Presenter: Rasha Al-Lamee

October 26, 2023

News Conference News CRT 2023

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Yael L. Maxwell

February 27, 2023

Presentation TCT 2022

Case-Based Presentation: Sex-Specific Considerations of Physiologic Assessment of CAD in the Cath Lab

Presenter: Rasha Al-Lamee

September 17, 2022

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

Advertisement

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Antianginals or Stents are Reasonable Alternatives for Patients with Symptomatic CAD

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Coronary Microvascular Disease -- How Do We Move the Field Forward?

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

My Step-by-step Approach to Avoid Common Mistakes in Measuring Invasive Physiology

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Case-Based Presentation: Sex-Specific Considerations of Physiologic Assessment of CAD in the Cath Lab

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content